Reolysin FDA Approval Status
FDA Approved: No
Brand name: Reolysin
Generic name: pelareorep
Company: Oncolytics Biotech Inc.
Treatment for: Ovarian Cancer, Pancreatic Cancer, Malignant Glioma
Reolysin (pelareorep) is a proprietary formulation of the human reovirus (Respiratory Enteric Orphan Virus) in development for the treatment of various cancers and cell proliferative disorders.
Development timeline for Reolysin
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
